Abel Hall LLC Takes $290,000 Position in Hims & Hers Health, Inc. $HIMS

Abel Hall LLC purchased a new position in Hims & Hers Health, Inc. (NYSE:HIMS) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 13,964 shares of the company’s stock, valued at approximately $290,000.

Other institutional investors have also added to or reduced their stakes in the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in Hims & Hers Health by 23.1% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 418,699 shares of the company’s stock valued at $12,373,000 after acquiring an additional 78,543 shares during the period. Geneos Wealth Management Inc. purchased a new stake in Hims & Hers Health in the first quarter worth about $30,000. EverSource Wealth Advisors LLC grew its holdings in Hims & Hers Health by 273.7% in the second quarter. EverSource Wealth Advisors LLC now owns 938 shares of the company’s stock worth $47,000 after purchasing an additional 687 shares during the period. Amundi increased its stake in shares of Hims & Hers Health by 5.3% during the second quarter. Amundi now owns 10,296 shares of the company’s stock valued at $489,000 after purchasing an additional 522 shares in the last quarter. Finally, California Public Employees Retirement System increased its stake in shares of Hims & Hers Health by 9.5% during the second quarter. California Public Employees Retirement System now owns 338,620 shares of the company’s stock valued at $16,880,000 after purchasing an additional 29,471 shares in the last quarter. Institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Price Performance

Shares of HIMS opened at $36.04 on Thursday. The company has a market capitalization of $8.34 billion, a P/E ratio of -400.44, a price-to-earnings-growth ratio of 101.79 and a beta of 2.35. The company has a quick ratio of 1.56, a current ratio of 1.69 and a debt-to-equity ratio of 2.18. The firm has a 50 day moving average of $29.05 and a 200 day moving average of $26.34. Hims & Hers Health, Inc. has a twelve month low of $13.74 and a twelve month high of $70.43.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings data on Monday, May 11th. The company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.44). The firm had revenue of $608.10 million during the quarter, compared to analysts’ expectations of $616.84 million. Hims & Hers Health had a positive return on equity of 6.10% and a negative net margin of 0.56%.Hims & Hers Health’s revenue was up 3.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.20 earnings per share. As a group, equities research analysts anticipate that Hims & Hers Health, Inc. will post 0.03 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, insider Irene Becklund sold 4,490 shares of the stock in a transaction on Wednesday, June 17th. The stock was sold at an average price of $31.50, for a total transaction of $141,435.00. Following the sale, the insider directly owned 6,790 shares of the company’s stock, valued at $213,885. This trade represents a 39.80% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director David B. Wells acquired 48,400 shares of Hims & Hers Health stock in a transaction that occurred on Tuesday, May 26th. The stock was acquired at an average price of $24.23 per share, with a total value of $1,172,732.00. Following the completion of the acquisition, the director directly owned 224,417 shares in the company, valued at $5,437,623.91. This represents a 27.50% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last quarter, insiders have sold 167,161 shares of company stock worth $5,041,152. 11.76% of the stock is owned by corporate insiders.

Analyst Ratings Changes

HIMS has been the subject of several recent research reports. Bank of America lifted their target price on shares of Hims & Hers Health from $25.00 to $36.00 and gave the company a “neutral” rating in a report on Wednesday, July 1st. Needham & Company LLC raised their price objective on Hims & Hers Health from $30.00 to $35.00 and gave the company a “buy” rating in a research report on Tuesday, May 12th. Canaccord Genuity Group lifted their price objective on Hims & Hers Health from $32.00 to $40.00 and gave the company a “buy” rating in a research note on Wednesday, July 1st. Zacks Research downgraded Hims & Hers Health from a “hold” rating to a “strong sell” rating in a report on Monday, June 8th. Finally, Barclays increased their target price on Hims & Hers Health from $29.00 to $39.00 and gave the stock an “overweight” rating in a research note on Wednesday, June 17th. Four investment analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $30.63.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.